5605-46-9

Usage

Uses

Used in Organic Synthesis:
(3R,5S)-5-(hydroxymethyl)-1-tosylpyrrolidin-3-ol is used as an intermediate in the synthesis of complex organic molecules. Its unique structure and functional groups make it a valuable building block for creating a wide range of compounds with diverse applications in various industries.
Used in Pharmaceutical Industry:
(3R,5S)-5-(hydroxymethyl)-1-tosylpyrrolidin-3-ol is used as a key component in the development of new drugs. Its chemical properties allow for the creation of potential therapeutic agents that can be used to treat various medical conditions.
Used in Chemical Research:
(3R,5S)-5-(hydroxymethyl)-1-tosylpyrrolidin-3-ol is used as a research tool in the study of organic chemistry. Its unique structure provides insights into the behavior of molecules and their interactions, contributing to the advancement of scientific knowledge in the field.

InChI:InChI=1S/C12H17NO4S/c1-9-2-4-12(5-3-9)18(16,17)13-7-11(15)6-10(13)8-14/h2-5,10-11,14-15H,6-8H2,1H3/t10-,11+/m0/s1

Upstream product

• 20275-18-7 N--trans-4-hydroxy-L-proline 
• 909262-73-3 4-hydroxy-1-tosylpyrrolidine-2-carboxylic acid 
• 618-27-9 hydroxy L-proline 
• 440678-43-3 cis-4-hydroxy-L-prolin-ethyl ester 
• 1379039-08-3 C₄₄H₅₃NO₃SSi₂ 
• 1379039-05-0 N-p-toluenesulfonyl-4(R)-amino-5-tert-butyldiphenylsilyl-1-tert-butyldiphenylsilyloxy-2(S)-pentanol 
• 51-35-4 4R-4-hydroxyproline 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 114086-15-6 (1S,4S)-2-Methyl-2,5-diazabicyclo<2.2.1>heptane Dihydrobromide 
• 125109-58-2 (1S,4S)-2-(4-Tolylsulfonyl)-5-methyl-2,5-diazabicyclo<2.2.1>heptane 
• 125109-57-1 (2S,4R)-1-(4-Tolylsulfonyl)-2-(chloromethyl)-4-((4-tolylsulfonyl)oxy)pyrrolidine 
• 127641-07-0 (1S,4S)-N-Benzyl-2,5-diazabicyclo-[2.2.1]heptane 
• 5234-72-0 (1S,4S)-5-Benzyl-2-tosyl-2,5-diazabicyclo<2.2.1>heptane 
• 141850-22-8 Hexanedioic acid mono-[(3R,5S)-1-(toluene-4-sulfonyl)-5-(toluene-4-sulfonyloxymethyl)-pyrrolidin-3-yl] ester 
• 141850-21-7 Hept-6-enoic acid (3R,5S)-1-(toluene-4-sulfonyl)-5-(toluene-4-sulfonyloxymethyl)-pyrrolidin-3-yl ester 
• 141850-61-5 Hexanedioic acid mono-[(3R,5S)-5-iodomethyl-1-(toluene-4-sulfonyl)-pyrrolidin-3-yl] ester 
• 141850-27-3 (1R,11S)-12-(Toluene-4-sulfonyl)-2,9-dioxa-12-aza-bicyclo[9.2.1]tetradecane-3,8-dione 
• 141850-28-4 (R)-5-Methylene-1-(toluene-4-sulfonyl)-pyrrolidin-3-ol 
• 569656-63-9 (2S)(2-tert-butyldiphenylsilyloxymethyl)-4,4-diallyl-1-(toluene-4-sulfonyl)pyrrolidine 
• 569656-77-5 [5-(tert-butyl-diphenyl-silanyloxymethyl)-1-(toluene-4-sulfonyl)-pyrrolidin-3-ylidene]-acetic acid ethyl ester 
• 1025889-74-0 1-bromomethyl-6-(tert-butyl-diphenyl-silanyloxymethyl)-5-(toluene-4-sulfonyl)-5-aza-spiro[2.4]heptane 
• 569656-62-8 [6-(tert-butyl-diphenyl-silanyloxymethyl)-5-(toluene-4-sulfonyl)-5-aza-spiro[2.4]hept-1-yl]-methanol 

Relevant academic research and scientific papers

Design, synthesis, and electrophysiological evaluation of NS6740 derivatives: Exploration of the structure-activity relationship for alpha7 nicotinic acetylcholine receptor silent activation

The α7 nicotinic acetylcholine receptor (nAChR) silent agonists, able to induce receptor desensitization and promote the α7 metabotropic function, are emerging as new promising therapeutic anti-inflammatory agents. Herein, we report the structure–activity

INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF

The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

A smooth rearrangement of N-p-toluenesulfonyl 2-tert- butyldiphenylsilylmethyl-substituted azetidines into N-p-toluenesulfonyl 3-tert-butyldiphenylsilyl-substituted pyrrolidines

The rearrangement of N-p-toluenesulfonyl 2-tert-butyldiphenylsilylmethyl- substituted azetidines into 3-tert-butyldiphenylsilyl-substituted pyrrolidines under Lewis acid conditions in dichloromethane involves 1,2-migration of silicon through a siliranium ion. The formation of siliranium ion was discovered not to be in concert with σC-N cleavage from stereochemical analysis of the pyrrolidine products formed from 3- and 4-substituted-2-tert- butyldiphenylsilylmethyl azetidines and also from the optical rotation data and chiral HPLC analysis of the pyrrolidine product formed from N-p-toluenesulfonyl 2(R)-tert-butyldiphenylsilylmethyl azetidine. The formation of sterically less hindered siliranium ion is followed by its SN2 opening by the internal nitrogen nucleophile. Oxidative cleavage of σC-Si bond leads to the formation of 3-hydroxypyrrolidines.

Synthesis of novel derivatives of (1S,4S)-2,5-diazabicyclo[2.2.1]heptane and their evaluation as potential ligands in asymmetric catalysis

Thirty-seven (most of them novel) chiral derivatives of (1S,4S)-2,5-diazabicyclo[2.2.1]heptane (2-36, 38, 39) were prepared from (S)-trans-4-hydroxyproline. A selection of these chiral ligands were examined as potential ligands in the preparation of catalysts for the enantioselective addition of diethylzinc to aldehydes and as chiral Lewis acid activators in the asymmetric Diels-Alder reaction. In the former system, diamine 30 induced up to 92 % enantiomeric excess in the formation of (S)-phenyl ethyl carbinol, whereas in the case of the cycloaddition reaction between cyclopentadiene and 3-acryloyloxazolidin-2-one the catalytic complex formed between dimeric derivative 8 and copper triflate [Cu(OTf)2] afforded the expected product in a 95:5 endo/exo ratio and up to 72 % ee for the major diastereomeric product. Finally, some of the novel chiral diamines prepared in this work were also evaluated as potential organocatalysts in the asymmetric amination of ethyl α-phenyl-α-cyano acetate. Bifunctional derivative 12 provided the animated product in excellent yield and with up to 40 % ee. Wiley-VCH Verlag GmbH & Co. KGaA, 2008.

Preparation of 2,5-diazabicyclo[2.2.1]heptanes and intermediates

(R,R)-2,5-Diazabicyclo[ 2.2.1]heptanes are prepared from a compound of the formula STR1 wherein X and R2 are as defined herein, by heating with tosylchloride in pyridine, reacting the formed compound of the formula STR2 with a C1 -C6 alkylamine or ammonia, and reducing or hydrolyzing the formed compound of the formula STR3 wherein R1 is hydrogen or C1 -C6 alkyl.

Agents for treatment of brain ischemia

A series of 5-halopyrimidin-2-ylpiperazinylalkyl derivatives having useful anti-ischemic properties for treatment and prevention of dirorders resulting from brain and/or spinal cord anoxia.

1-indolyalkyl-4-(substituted-pyridinyl)piperazines

A series of 1,4-disubstituted piperazine derivatives comprised of indol-3-ylalkyl and substituted pyridin-2-yl substituent groups. These compounds are useful as antidepressant agents.

Rhodium complexes of chiral phosphines

Novel chiral phosphines are disclosed which when complexed with rhodium provide catalyst compositions for asymmetric hydrogenations.